U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07379788) titled 'ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling' on Jan. 23.
Brief Summary: This study aimed to compare the effects of ARNI monotherapy versus combined ARNI and SGLT2 inhibitor therapy on Mitral Remodeling Index (MRIx) and Functional mitral regurgitation (FMR) remodeling in patients with heart failure with reduced ejection fraction (HFrEF).
Study Start Date: Dec. 25, 2025
Study Type: OBSERVATIONAL
Condition:
Heart Failure
Intervention:
DRUG: Sacubitril/Valsartan 49 MG-51 MG Oral Tablet [ENTRESTO]
Patients receiving Sacubitril/Valsartan 49 MG-51 MG Oral Tablet without concomitant SGLT2 inhibit...